Evaluating a Glioma Transcriptomic Signature Against a Clinical Reference Model and a Random-Signature Null Distribution: A Leakage-Controlled Internal Audit and a Survey of the Field.

Yasar S, Yagin B, Alzakari SA, Alkhalifa AK, Al-Hashem F, Tabnjh AK

Open source

DOI
10.3390/diagnostics16172803
Published
2026 Aug 31
Container
Diagnostics (Basel, Switzerland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/diagnostics16172803,
  title = {Evaluating a Glioma Transcriptomic Signature Against a Clinical Reference Model and a Random-Signature Null Distribution: A Leakage-Controlled Internal Audit and a Survey of the Field.},
  author = {Yasar S and Yagin B and Alzakari SA and Alkhalifa AK and Al-Hashem F and Tabnjh AK},
  year = {2026},
  journal = {Diagnostics (Basel, Switzerland)},
  doi = {10.3390/diagnostics16172803},
  url = {https://doi.org/10.3390/diagnostics16172803}
}

RIS

TY  - JOUR
TI  - Evaluating a Glioma Transcriptomic Signature Against a Clinical Reference Model and a Random-Signature Null Distribution: A Leakage-Controlled Internal Audit and a Survey of the Field.
AU  - Yasar S
AU  - Yagin B
AU  - Alzakari SA
AU  - Alkhalifa AK
AU  - Al-Hashem F
AU  - Tabnjh AK
PY  - 2026
JO  - Diagnostics (Basel, Switzerland)
DO  - 10.3390/diagnostics16172803
UR  - https://doi.org/10.3390/diagnostics16172803
ER  - 

APA

S, Y., B, Y., SA, A., AK, A., F, A., & AK, T. (2026). Evaluating a Glioma Transcriptomic Signature Against a Clinical Reference Model and a Random-Signature Null Distribution: A Leakage-Controlled Internal Audit and a Survey of the Field.. Diagnostics (Basel, Switzerland). https://doi.org/10.3390/diagnostics16172803

Source records